Novel Acetamide Indirectly Targets Mycobacterial Transporter MmpL3 by Proton Motive Force Disruption

To identify novel inhibitors of cell envelope biosynthesis, we employed a two-step approach. First, we screened the diverse synthetic small molecule 71,544-compound Enamine library for growth inhibitors using the non-pathogenic surrogate BCG as screening strain and turbidity as readout. Second, 16 c...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 9; p. 2960
Main Authors Shetty, Annanya, Xu, Zhujun, Lakshmanan, Umayal, Hill, Jeffrey, Choong, Meng Ling, Chng, Shu-Sin, Yamada, Yoshiyuki, Poulsen, Anders, Dick, Thomas, Gengenbacher, Martin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.12.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To identify novel inhibitors of cell envelope biosynthesis, we employed a two-step approach. First, we screened the diverse synthetic small molecule 71,544-compound Enamine library for growth inhibitors using the non-pathogenic surrogate BCG as screening strain and turbidity as readout. Second, 16 confirmed hits were tested for their ability to induce the cell envelope stress responsive promoter p controlling expression of red fluorescent protein in an BCG reporter strain. Using a fluorescence readout, the acetamide E11 was identified. Resistant mutant selection and whole genome sequencing revealed the mycolic acid transporter Mmpl3 as a candidate target of E11. Biochemical analysis using mycobacterial spheroplasts and various membrane assays suggest that E11 indirectly inhibits MmpL3-facilitated translocation of trehalose monomycolates by proton motive force disruption. E11 showed potent bactericidal activity against growing and non-growing , low cytotoxic, and hemolytic activity and a dynamic structure activity relationship. In addition to activity against , E11 was active against the non-tuberculous mycobacterium , an emerging opportunistic pathogen. In conclusion, we identified a novel bactericidal anti-mycobacterial lead compound targeting MmpL3 providing an attractive starting point for optimization.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Henrietta Venter, University of South Australia, Australia
Reviewed by: Sandeep Sharma, Lovely Professional University, India; Mario Alberto Flores-Valdez, CONACYT Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Mexico; Tavan Janvilisri, Mahidol University, Thailand
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2018.02960